Earnings Call · Q4 FY2023·2024-03-20

Q4 23EPS 0.00%·Rev n/aQ3 23EPS +7.69%·Rev n/aQ2 23EPS +11.11%·Rev n/aQ1 23EPS -25.00%·Rev n/a⚠ consensus missing

DiaMedica Therapeutics Inc. DMAC

Dietrich Pauls — Chief Executive Officer

Lorianne Masuoka — Chief Medical Officer

Scott Kellen — Chief Financial Officer

−1.8%1d on move date−2.7% vs SPY3d−2.5%5d−3.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DMAC calls or request research access.

More DMAC calls Browse calls Request research access